Related articles

• Randomized Controlled Trial

  AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the...

  J. Am. Coll. Cardiol. 2014 Feb 11;63(5):430-3.

• Randomized Controlled Trial

  Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the...

  Bmc Cardiovasc Disor. 2014 Jan 1;14:121.

• Review

  An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.

  Cardiovasc Ther. 2014 Apr 1;32(2):82-8.

Show more related articles...